Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara presented new biomarker data from the double-blind period of its pivotal IMPALA-2 Phase 3 trial for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP). The data showed that molgramostim significantly improved pulmonary gas transfer (DLco%) at Weeks 24 and 48 versus placebo, with p-values of 0.0007 and 0.0008 respectively.
Key figures
- Drug Name
- molgramostim
- Phase Of Trial
- Phase 3
- Trial name
- IMPALA-2
- Placebo group n
- 83
- Treatment group n
- 81
- Kl6 week24 p value
- 0.0016
- Kl6 week48 p value
- 0.0022
- Ldh week24 p value
- 0.015
- Ldh week48 p value
- 0.0051
- Dlco week24 p value
- 0.0007
- Dlco week48 p value
- 0.0008
- Cyfra week24 p value
- 0.0036
- Cyfra week48 p value
- 0.0017
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.